Lexicon Share Spike On Carcinoid Syndrome Phase III Data
This article was originally published in Scrip
Executive Summary
Lexicon Pharmaceuticals Inc. is looking forward to filing its first US NDA after announcing positive top-line Phase III data for its lead product, telotristat etiprate, in treating cancer patients with carcinoid syndrome inadequately controlled by the current standard of care. Shares in the firm shot up by 47% to $12.41 on NASDAQ the morning of Aug. 1, 2015 following the news.
You may also be interested in...
Third Phase III Success Puts Lexicon/Sanofi's Sotagliflozin On Track For NDA Filing
Intended mainly to provide evidence of a safety advantage compared to existing SGLT2 inhibitors, meeting the net-benefit primary endpoint in the inTandem3 trial puts sotagliflozin in good shape for approval as add-on glycemic-control therapy in type 1 diabetes.
Nine Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are nine (plus a few extras) that have caught attention for one reason or another, e.g., for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.
10 Pivotal Studies To Look Out For In 2024
While not expected to be quite so busy as previous years, 2024 will still see many pivotal clinical trial readouts that should create a splash. Here are ten (plus a few extras) that have caught Scrip’s eye for one reason or another, eg, for being the first readout for a novel drug class, having the potential to take a product in a new lucrative direction, for maybe being able to succeed where a rival has already failed or even for having been a long time coming.